Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-04-30 Sale | 2025-05-01 7:07 pm | Acrivon Therapeutics Inc. | ACRV | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 736,767 | $1.3816 | $1,017,919 | 3,104,139 (Indirect) | View |
| 2025-04-25 Sale | 2025-04-29 7:26 pm | Acrivon Therapeutics Inc. | ACRV | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 1,519,952 | $1.8059 | $2,744,946 | 3,840,906 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-06-13 Option Award | 2025-06-17 8:17 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 20,275 | $0 | 20,275 (Indirect) | View |
| 2025-06-13 Option Award | 2025-06-17 6:04 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | DiRocco Derek Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-06-13 Option Award | 2025-06-17 5:57 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | TOMSICEK MICHAEL JOHN Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-06-13 Option Award | 2025-06-17 5:54 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | Shacham Sharon Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-06-13 Option Award | 2025-06-17 5:49 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | Palani Santhosh Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-06-13 Option Award | 2025-06-17 5:48 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | Magovcevic-Liebisch Ivana Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-06-13 Option Award | 2025-06-17 5:21 pm | N/A 2035-06-12 | Acrivon Therapeutics Inc. | ACRV | BAUM CHARLES M Director | 20,275 | $0 | 20,275 (Direct) | View |
| 2025-05-21 Tax Withholding | 2025-05-23 4:58 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 19,904 | $1.15 | 2,521,797 (Direct) | View |
| 2025-05-14 Tax Withholding | 2025-05-16 4:21 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Peterson Katharine Chief Accounting Officer | 99 | $1.14 | 4,320 (Direct) | View |
| 2025-05-14 Tax Withholding | 2025-05-16 4:20 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 184 | $1.14 | 36,323 (Direct) | View |
| 2025-05-14 Tax Withholding | 2025-05-16 4:18 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Gamelin Erick Chief Development Officer | 403 | $1.14 | 16,089 (Direct) | View |
| 2025-05-14 Tax Withholding | 2025-05-16 4:17 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Devroe Eric Chief Operating Officer | 613 | $1.14 | 66,534 (Direct) | View |
| 2025-05-14 Tax Withholding | 2025-05-16 4:16 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 60,257 | $1.14 | 2,541,701 (Direct) | View |
| 2025-04-17 Tax Withholding | 2025-04-18 3:51 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 558 | $1.81 | 36,507 (Direct) | View |
| 2025-04-01 Option Award | 2025-04-03 4:32 pm | N/A 2035-03-31 | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 15,616 | $0 | 15,616 (Direct) | View |
| 2025-04-01 Option Award | 2025-04-03 4:30 pm | N/A 2035-03-31 | Acrivon Therapeutics Inc. | ACRV | Levy Adam D. Chief Financial Officer | 35,209 | $0 | 35,209 (Direct) | View |
Ownership | 2025-04-03 4:28 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Levy Adam D. Chief Financial Officer | 0 | $0 | 169,340 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:36 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Peterson Katharine Chief Accounting Officer | 31,900 | $0 | 31,900 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:31 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 93,693 | $0 | 93,693 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:28 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Holm-Jorgensen Rasmus Chief Financial Officer | 109,309 | $0 | 109,309 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:24 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Gamelin Erick Chief Development Officer | 78,078 | $0 | 78,078 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:21 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Devroe Eric Chief Operating Officer | 140,540 | $0 | 140,540 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:13 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Cuillerot Jean-Marie Chief Medical Officer | 78,078 | $0 | 78,078 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 5:11 pm | N/A 2035-02-28 | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 530,930 | $0 | 530,930 (Direct) | View |
| 2025-02-21 Tax Withholding | 2025-02-25 4:09 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 19,904 | $5.54 | 2,601,958 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 5:00 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Peterson Katharine Chief Accounting Officer | 116 | $5.42 | 4,419 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 4:59 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 217 | $5.42 | 37,065 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 4:55 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Holm-Jorgensen Rasmus Chief Financial Officer | 434 | $5.42 | 26,088 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 4:54 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Gamelin Erick Chief Development Officer | 469 | $5.42 | 16,492 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 4:53 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Devroe Eric Chief Operating Officer | 724 | $5.42 | 67,147 (Direct) | View |
| 2025-02-14 Tax Withholding | 2025-02-19 4:52 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 37,731 | $5.42 | 2,621,862 (Direct) | View |
| 2025-01-17 Tax Withholding | 2025-01-22 4:15 pm | N/A N/A | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 659 | $5.78 | 37,282 (Direct) | View |
| 2024-03-01 Option Award | 2024-11-27 6:11 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Miller Mary Chief Legal Officer | 67,567 | $0 | 67,567 (Direct) | View |
| 2024-03-01 Option Award | 2024-11-27 6:10 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Holm-Jorgensen Rasmus Chief Financial Officer | 90,090 | $0 | 90,090 (Direct) | View |
| 2024-03-01 Option Award | 2024-11-27 6:08 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Gamelin Erick Chief Development Officer | 45,045 | $0 | 45,045 (Direct) | View |
| 2024-03-01 Option Award | 2024-11-27 6:06 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Devroe Eric Chief Operating Officer | 90,090 | $0 | 90,090 (Direct) | View |
| 2024-03-01 Option Award | 2024-11-27 6:04 pm | N/A 2034-02-28 | Acrivon Therapeutics Inc. | ACRV | Blume-Jensen Peter Masson Kristina President and CEO | 315,316 | $0 | 315,316 (Direct) | View |